Combination of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in treatment of advanced extranodal NK/T-cell lymphoma-Reference-Cited by-同舟云学术

Combination of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in treatment of advanced extranodal NK/T-cell lymphoma

Published:2023-03-20 Issue:6 Volume:136 Page:732-734
ISSN:0366-6999
Container-title:Chinese Medical Journal
language:en
Short-container-title:

Author:

Fu Ruiying¹,Liang Yuanzheng¹,Wei Liqiang¹,Liu Xindi¹,Piao Yingshi²³,Wang Liang¹³

Affiliation:

1. Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China

2. Department of Pathology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China

3. Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine,General Medicine

Reference9 articles.

1. Extranodal natural-killer T-cell lymphoma: experience from China;Wang;Lancet Haematol,2020

2. Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis;Wei;J Cancer Res Clin Oncol,2021

3. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis;Henter;Pediatr Blood Cancer,2007

4. Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma;Wang;Oncotarget,2016

5. Efficacy and safety of a pegasparaginase-based chemotherapy regimen vs. an L-asparaginase-based chemotherapy regimen for newly diagnosed advanced extranodal natural killer/T-cell lymphoma: a randomized clinical trial;Wang;JAMA Oncol,2022

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety analysis of combination therapy based on mitoxantrone hydrochloride liposome injection (Lipo-MIT) in relapsed/refractory NK/T-cell lymphoma;Frontiers in Oncology;2024-06-21